From Concept to Practice: Enabling the Next Generation of MRD & Biomarker-Guided Trials
- Recently announced topline results from a prospective, randomized Phase III trial showed that Signatera-positive patients treated with an investigational therapy experienced statistically significant and clinically meaningful improvements in DFS and OS, demonstrating the feasibility of MRD-guided trial designs in an adjuvant setting
- Natera has since expanded beyond ultra-sensitive tumor-informed and tissue-free MRD assays to offer comprehensive genomic profiling (CGP), methylation, and trial support services enabled by real-world data and AI
- Together, these capabilities help sponsors design and execute MRD- and biomarker-guided trials with greater confidence and efficiency, offering broader optionality to tailor biomarker strategies across indications